December 22, 2022 Ryvu Therapeutics announces closing of equity offering with gross proceeds over PLN 250 million
Read More
December 11, 2022 Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read More
December 8, 2022 Ryvu Therapeutics initiates public offering of shares
Read More
November 30, 2022 BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates
Read More
November 23, 2022 Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Read More
November 3, 2022 Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read More
October 26, 2022 Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
October 12, 2022 Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
September 28, 2022 Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update
Read More
August 19, 2022 Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission
Read More
Posts navigation
